The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed.Due to growing demand for specialized treatments and increasi
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed.Across the clinical manufacturing landscape, one priority is
CellBion, a prominent Korean pharmaceutical company, has announced that its groundbreaking prostate cancer drug, Lu-177-DGUL, is attracting considerable attention.On Monday, the Ministry of Food and Drug Safety (MFDS) designated Lu-177-DGUL as the 11th agent to benefit from its “Global Innovative Pr
Domestic pharmaceutical companies have been noticeably jumping into the CDMO business, particularly in the drug substance (DS) and drug product (DP) areas. However, Vetter still sees a need to bridge the gap between clients' DS and DP manufacturing to meet international requirements in the EU and U.
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed.With the increasing drug development for novel therapeutics,
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed. The demand for complex, often life-saving drug substances su
CellBion said Wednesday it has signed a development, manufacturing, and supply agreement with the Centre for Probe Development and Commercialization (CPDC), a Canadian radiopharmaceuticals company, for Lu-177-radiolabelled prostate-specific membrane antigen (PSMA-DGUL) therapeutic agent.Under the ac
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed. Vetter, a globally operating Contract Development and Manufa
Maria Medical Technology (MMT), a manufacturer of aesthetic devices and medical robots based in the United Arab Emirates, has released an automated, artificial intelligence-based medical robot for hair removal, iLaser.MMT makes medical “cobots,” robots designed to work collaboratively with humans wi
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed. The Asia-Pacific (APAC) region is among the world’s fastest-
Maria Trading, a trusted distributor of medical aesthetics products in the United Arab Emirates (UAE), has signed an agreement with a Korean company, Coous Global, to supply Coresculpt 2CH, which helps build up muscles.Maria Trading was founded in 2004 and has since delivered promising aesthetics de
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed. In the health care industry, changes are occurring at a rapi